Adaptimmune Therapeutics plc Stock News

Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.

Adaptimmune (ADAP) surges on the completion of the rolling submission, with the FDA seeking approval for its most advanced pipeline candidate as the first engineered cell therapy for solid tumors.

Adaptimmune (ADAP) shares rise as GSK transfers IND for letetresgene autoluecel (lete-cel), which is being developed for treating synovial sarcoma and myxoid/round cell liposarcoma.

Adaptimmune Therapeutics PLC (ADAP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising

The latest trading day saw Adaptimmune Therapeutics PLC (ADAP) settling at $0.60, representing a +1.5% change from its previous close.

The latest trading day saw Adaptimmune Therapeutics PLC (ADAP) settling at $0.55, representing a -1.79% change from its previous close.

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - October 25, 2023) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, will report fin

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 3, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include OpGen (OPGN), Adaptimmune Therapeutics (ADAP), Valmont Industries (VMI), Versus Systems (VS) and

GSK announces the FDA's extension of the review period of its new drug application for momelotinib to treat myelofibrosis by three months. A decision is now expected on Sep 16, 2023.

The heavy selling pressure might have exhausted for Adaptimmune Therapeutics PLC (ADAP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wa

Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q1 2023 Earnings Conference Call May 12, 2023 8:00 AM ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief Executive Offic

Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include Sweetgreen (SG), Adaptimmune Therapeutics (ADAP), Owl Rock Capital (ORCC), MACOM Technology Solutions (

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - April 28, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report fina

Adaptimmune Therapeutics (ADAP) enters into a transition deal with GSK to regain rights to its proprietary T-cell therapy programs. Shares of the company surges 7% following the news.